Nakamura 2012a.

Methods	Study design: parallel, double‐blind RCT Duration of study: not reported Follow‐up: 12 months ADPKD assessment: Echo
Participants	Country: Japan Setting: single centre ADPKD; good kidney function; microalbuminuria; hypertension (BP > 140/90 mm Hg) Number: treatment group (10); control group (10) Mean age ± SD (years): treatment group (57 ± 6); control group (58 ± 6) Sex (M/F): treatment group (6/4); control group (5/5) Exclusion criteria: SCr > 1.0 mg/dL; eGFR < 60 mL/min; aged < 20 or > 80 years; current smoker Additional exclusion criteria were 1 or more of the following: presence of another kidney disease; DM; CHF; IHD; PVD; liver disease; malignancy; collagen disease; CVA within the prior 6 months
Interventions	Treatment group Telmisartan: 80 mg/d Control group Enalapril: 10 mg/d Duration of intervention 12 months
Outcomes	BP UAE inflammatory stress markers
Notes	Funding source: not reported
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Insufficient information to permit judgement
Allocation concealment (selection bias)	Unclear risk	Insufficient information to permit judgement
Blinding of participants and personnel (performance bias) All outcomes	Low risk	Double‐blind
Blinding of outcome assessment (detection bias) All outcomes	Unclear risk	Insufficient information to permit judgement
Incomplete outcome data (attrition bias) All outcomes	Unclear risk	Insufficient information to permit judgement
Selective reporting (reporting bias)	Unclear risk	Insufficient information to permit judgement
Other bias	Unclear risk	Insufficient information to permit judgement